Pavmed Inc. · NASDAQ:PAVM
Pavmed — IPO Roadshow (December 2015)
32 slides from Pavmed's IPO roadshow presentation, Dec 1, 2015
Slide 1: PAVmed - Innovating at the Speed of Life
SX PAVmed INNOVATING AT THE SPEED OF LIFE™ DECEMBER 2015
Slide 2: Disclaimer
2 Disclaimer PAVMED INC. (“PAVMED”) HAS FILED A REGISTRATION STATEMENT (INCLU DING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS PAVMED HAS FILED WITH THE SEC FOR M
Slide 3: Company Overview
3 Company Overview
Slide 4: PAVmed Inc.
4 PAVmed Inc. PAVmed is an innovative multi - product medical device company, led by a team of entrepreneurs with a strong record of value creation, employing a proven capital and time efficient business model to advance an expanding pipeline of innovative products from concept to commercialization
Slide 5: An innovative multi-product medical device company
5 An innovative multi - product medical device company Unique, proven business model ▪ Speed to market ▪ Highly capital efficient ▪ High - margin, high - impact products addressing unmet clinical needs in attractive markets Led by a team of accomplished medical device entrepreneurs with a strong rec
Slide 6: Corporate Milestones Achieved
6 Corporate Milestones Achieved Founded in June 2014 Raised ~$1,000,000 in seed capital Recruited world - class Board of Directors Recruited Medical Advisory Board, of renowned physician innovators across multiple clinical specialties Filed provisional patents for all lead projects and final patent
Slide 7: Leadership team with strong record of value creation
7 Leadership team with strong record of value creation Accomplished entrepreneurs who have worked together in medical device innovation and commercialization since founding Pavilion Holdings Group and Pavilion Medical Innovations LISHAN AKLOG, MD C HAIRMAN & CEO ▪ A.B. Physics, magna cum laude ▪ Phi
Slide 8: Leadership team's prior track record of success
8 Leadership team’s prior track record of success At Pavilion Holdings Group the leadership team created four single - product companies which rapidly advanced their products towards commercialization creating significant value with modest capital investment. COMPANY PRODUCT CAPITALIZATION COMMERCIA
Slide 9: PAVmed builds on the leadership team's prior success
9 PAVmed builds on the leadership team’s prior success The leadership team created PAVmed to leverage their proven business model in a long - term multi - product company with access to seamless capital through the public capital markets. PAVmed’s structure enables it to retain the model’s tight foc
Slide 10: Lead products provide near-term value creation opportunities
10 Lead products provide near - term value creation opportunities NextCath Self - Anchoring Short - Term Catheters Target Commercialization Q4 - 2016 NextFlo Highly Accurate Disposable Infusion Pump T arget Commercialization Q4 - 2016 PortIO Long - term Implantable Vascular Access Device Target Comm
Slide 11: The PAVmed Business Model
11 The PAVmed Business Model
Slide 12: Proven record of delivering capital and time efficiency
12 Proven record of delivering capital and time efficiency 0 12 24 36 48 60 Typical Company PAVmed Model Months T IME TO 510( K ) C LEARANCE $0 $10,000,000 $20,000,000 $30,000,000 Typical Company PAVmed Model Dollars C APITAL T O 510( K ) C LEARANCE * Typical Company data from Markower, et al. FDA I
Slide 13: Project selection criteria drive commercial opportunity
13 Project selection criteria drive commercial opportunity COMMERCIAL OPPORTUNITY High - Margin High - Impact UNMET CLINICAL NEED IN ATTRACTIVE MARKET TECHNOLOGY PROFILE REGULATORY PATHWAY REIMBURSEMENT PROFILE
Slide 14: Key business processes deliver capital and time efficiency
14 Key business processes deliver capital and time efficiency CAPITAL AND TIME EFFICIENCY Maximize Value Creation LIGHT INFRASTRUCTURE/ LOW FIXED COSTS PARALLEL DEVELOPMENT PROCESSES OUTSOURCED BEST - IN - CLASS PROCESS EXPERTS RAPID COMMERCIALIZATION STRATEGY
Slide 15: Multi-product pipeline enhances value creation
15 Multi - product pipeline enhances value creation ENHANCED VALUE CREATION ECONOMIES OF SCALE FLEXIBLE, DYNAMIC ALLOCATION OF RESOURCES FLEXIBLE COMMERCIALIZATION STRATEGY NON - BINARY SUCCESS
Slide 16: Flexible commercialization strategy accelerates value creation
16 Flexible commercialization s trategy accelerates value creation DIRECT SALES FORCE Call - point specific INDEPENDENT DISTRIBUTOR NETWORK Call - point specific REGULATORY CLEARANCE CORPORATE PARTNER Sales and Distribution A greement CORPORATE PARTNER Licensing agreement Acquisition of product Init
Slide 17: Product Pipeline
17 Product Pipeline
Slide 18: Lead products provide near-term value creation opportunities
18 PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE PortIO Long - term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors Q4 - 2016 Caldus Disposable Tissue Ablation Devices $200M/$100M 510(k) Independent Distributors Q2 - 2017 Disp
Slide 19: Patent applications by product
19 PRODUCT INVENTORS TITLE NUMBER DATE PortIO Aklog, deGuzman and Orphanos “Intraosseous Infusion Ports and Methods of Use” Application# US62/0.79.266 US14940889 PCT/US15/60669 Filed 13 - Nov - 2014 13 - Nov - 2015 13 - Nov - 2015 Caldus Aklog and deGuzman “Continuous Flow Balloon Catheter Systems a
Slide 20: PortIO: Long-Term Implantable Vascular Access Device
20 PortIO: Long - Term Implantable Vascular Access Device MARKET OPPORTUNITY C LINICAL ▪ Implantable vascular access devices for delivery of medications and other substances over weeks to months A DDRESSABLE M ARKET ▪ Total: All i mplantable ports 1 ~$500M Immediate: Poor venous access patients ~$50
Slide 21: Caldus: Disposable Tissue Ablation Devices including Renal Denervation
21 Caldus: Disposable Tissue Ablation Devices including Renal Denervation MARKET OPPORTUNITY C LINICAL ▪ Ablation of pathologic soft tissues including tumors ▪ Renal denervation for refractory hypertension T OTAL /I MMEDIATE A DDRESSABLE M ARKET ▪ General soft tissue ablation ~$200M/$100M 1 Renal de
Slide 22: CarpX: Percutaneous Device to Treat Carpal Tunnel Syndrome
22 CarpX: Percutaneous Device to Treat Carpal Tunnel Syndrome MARKET OPPORTUNITY C LINICAL ▪ Carpal tunnel syndrome (CTS) ▪ Most common cumulative trauma disorder and occupational injury A DDRESSABLE M ARKET ▪ ~2 million patients and 350,000 surgeries annually 1 ▪ Total: All CTS patients $1.5B Immed
Slide 23: NextCath: Self-Anchoring, Short-Term Catheters
23 NextCath: Self - Anchoring, Short - Term Catheters MARKET OPPORTUNITY C LINICAL ▪ Short - term catheters including peripheral venous catheters (PVC) and central venous catheters (CVC) A DDRESSABLE M ARKET 1 ▪ 90% of inpatients receive a PVC ▪ ~7 million patients receive a CVC annually ▪ Total: Al
Slide 24: NextFlo: Highly Accurate Disposable Infusion Pumps
24 NextFlo: Highly Accurate Disposable Infusion Pumps MARKET OPPORTUNITY C LINICAL ▪ Disposable infusion pumps (DIP) ▪ Increasing numbers receiving infusions outside hospital ▪ DIPs favored for home infusions because they are small, easy to conceal, enhance mobility A DDRESSABLE M ARKET ▪ Total/Imme
Slide 25: The PAVmed Team
25 The PAVmed Team
Slide 26: Experienced management team with record of value creation
26 Experienced management team with record of value creation LISHAN AKLOG, MD Chairman and Chief Executive Officer • Co - founding Partner, Pavilion Holdings Group and Pavilion Medical Innovations • Former Chairman and Chief Technology Officer, Vortex Medical • Former Associate Professor, Chief of C
Slide 27: Board of Directors with industry and capital markets experience
27 Board of Directors with industry and capital markets experience LISHAN AKLOG, MD Chairman, Chief Executive Officer MICHAEL GLENNON Vice - Chairman RONALD M. SPARKS Director Nominating Committee Chair ▪ Former Healthcare Industry Executive, Avista Capital Partners ▪ Former Chairman and CEO, Navily
Slide 28: Multi-Specialty Medical Advisory Board of renowned physician innovators
28 Multi - Specialty Medical Advisory Board of renowned physician innovators ALBERT CHIN MD ▪ Co - founding Partner and Chief Innovation Officer, Pavilion Medical Innovations ▪ Former Vice President of Research and Chief Innovation Officer, Maquet Cardiovascular/ Guidant Cardiac Surgery ▪ Inventor o
Slide 29: The Future of PAVmed
29 The Future of PAVmed
Slide 30: Expand pipeline in order to drive long-term growth
30 Expand pipeline in order to drive long - term growth Additional internal projects currently in conceptual phase addressing ▪ Extracorporeal circulation (ECMO) cannulas ▪ Left atrial access for transcatheter mitral intervention ▪ Endotracheal intubation ▪ Sleep apnea ▪ Laparoscopic hernia r epair
Slide 31: Abundant near- and long-term opportunities for value creation
31 Abundant near - and long - term opportunities for value creation 2016 M ILESTONES Complete lead product non - provisional patent applications PortIO FDA submission NextCath FDA submission NextFlo FDA submission PortIO FDA clearance and initial commercialization Caldus General FDA submission Caldu
Slide 32: PAVmed Investment Highlights
32 Unique, Proven Business Model Broad, Expanding Pipeline of Innovative Products World - Class Board and Advisors Leadership Team with Strong Record of Value Creation PAVmed Investment Highlights INNOVATING AT THE SPEED OF LIFE TM TM